Penn Medicine’s Center for Cellular Immunotherapies (CCI) is at the forefront of revolutionizing cancer treatment through CAR (chimeric antigen receptor) T cell therapy. This innovative approach harnesses the power of the patient’s own immune system to target and destroy cancer cells, offering new
CAR-T cell therapy has emerged as a groundbreaking approach in cancer treatment, leveraging the body's immune system to target and destroy cancer cells. Since its inception in 2017, this innovative therapy has rapidly evolved, with numerous products reaching commercialization and receiving
The rise in skin cancer cases worldwide has necessitated the exploration of innovative and more efficient treatments. Among the promising solutions is immunotherapy for cancer, a revolutionary method known for its effectiveness. However, this approach is often expensive and may cause severe side
The concept of treating neurodegenerative diseases with stem cell therapy has captivated the medical community for decades, presenting a potential breakthrough in the race to cure diseases like Alzheimer's, Parkinson's, and multiple sclerosis. Stem cells, with their extraordinary ability to
A significant milestone in pediatric medical care was recently achieved with the FDA's approval of Ryoncil (remestemcel-L-rknd), a revolutionary cell therapy designed for children suffering from steroid-refractory acute graft-versus-host disease (SR-aGVHD). This breakthrough therapy marks the
Recent research from Penn Medicine has uncovered a potentially groundbreaking approach to enhance the effectiveness of CAR T cell therapy, a highly personalized cancer treatment designed to reprogram immune cells to target and destroy cancer cells. The crux of the discovery lies in the idea that a
